戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y cancer surgery are treated briefly with an investigational agent).
2 CL01, which is the first human study of this investigational agent.
3  audiologic testing for potentially ototoxic investigational agents.
4 therapy, chemotherapy, or clinical trials of investigational agents.
5 m, which oversees clinical trial efforts for investigational agents.
6 aches to screen for the DILI potential of an investigational agent and provide a high-level descripti
7 in clinical trials, the DILI potential of an investigational agent and risks to a participant are car
8 se some of the agents used may interact with investigational agents and affect adverse effects and/or
9 onse by various factors such as cancer type, investigational agent, and trial design.
10  of novel targeted treatment options and new investigational agents, and advances in radiotherapy tec
11 alance patient safety, access to appropriate investigational agents, and study integrity.
12 aemoglobin concentration), enrolment period, investigational agents, and trial design were assessed u
13 ion in children is critical, since many more investigational agents are evaluated in adult patients t
14                                              Investigational agents are not likely to provide an alte
15                            A large number of investigational agents are under development for treatme
16 s to fluconazole remained susceptible to the investigational agents as well as to amphotericin B and
17  recommendations are applicable to trials of investigational agents as well as various classes of dru
18                                              Investigational agents based on hypothesized causes are
19 uenza neuraminidase inhibitors are promising investigational agents, but remaining issues include pro
20 on of 304 inhibitors, including approved and investigational agents, comparing ex vivo responses of p
21 an derive benefit from the many approved and investigational agents developed through years of collab
22  signals of excessive toxicity and premature investigational agent discontinuation observed in early
23                                          The investigational agent elironrasib is currently undergoin
24  neoadjuvant therapy with or without 1 of 10 investigational agents, followed by definitive surgery.
25 a randomized, placebo-controlled trial of an investigational agent for traumatic brain injury.
26 nhibitor-free protocol inclusive of a single investigational agent for use in clinical islet transpla
27 oadjuvant paclitaxel plus/minus 1 of several investigational agents for 12 weeks, then 12 weeks of cy
28  checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cer
29 suppression with use of better-tolerated and investigational agents for unfit patients and those with
30                The preclinical evaluation of investigational agents for Waldenstrom macroglobulinemia
31                                         This investigational agent has proven superior to selective G
32 pathic pulmonary fibrosis, a number of novel investigational agents hold promise for future study.
33            However, it later found use as an investigational agent in the treatment of erythema nodos
34 l trial in the US that compares, by subtype, investigational agents in combination with chemotherapy
35 (SPU) mechanism to provide patient access to investigational agents in situations where no satisfacto
36 -L1-targeting therapy, with or without other investigational agents, in patients with MSS metastatic
37 eceived uncontrolled treatment with multiple investigational agents, including convalescent plasma, w
38 ble liberal creatinine clearance, unless the investigational agent involves renal excretion.
39          Here, we show that a combination of investigational agents-ixazomib plus venetoclax-which re
40                                          The investigational agent maribavir has shown promise as pre
41 candidate therapeutic targets and respective investigational agents, may pose formidable challenges f
42 ce, selective p110alpha inhibition using the investigational agent MLN1117 (previously known as INK11
43 proved antibiotic, and that entinostat is an investigational agent not yet FDA-approved, we propose e
44  patients in groups 2 and 3 who received the investigational agent or placebo.
45  primary outcome of CAPTIVATE is to identify investigational agents or combinations of agents to redu
46                  CAPTIVATE will test several investigational agents or combinations of agents, beginn
47 ecent clinical trials, such as those for the investigational agents, oral plasma kallikrein inhibitor
48     Within a backup program for the clinical investigational agent pretomanid (PA-824), scaffold hopp
49  to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for poste
50    We also analysed cancer type-specific and investigational agent-specific response, and analysed th
51  vaccinia immune globulin and who received 2 investigational agents, ST-246 and CMX001.
52 secondary end point was reported from the 10 investigational agents tested in the I-SPY2 trial from M
53         Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits b
54  strategy of integrating clinically relevant investigational agents that cooperate mechanistically th
55  provide an ideal group in which to test new investigational agents that might have potential as main
56 of the disease have opened the door to study investigational agents that target disrupted molecular p
57 teristics of the experimental trials and the investigational agents, the odds of a patient dying from
58 nsent in this placebo-controlled trial of an investigational agent was high and exceeded acceptance a
59 comes confirmed clinician reporting that the investigational agent was well tolerated and, in subgrou
60     Allogeneic stem-cell transplantation and investigational agents were associated with a better out
61 0 [80%] White individuals) from the first 10 investigational agents were included, with a median foll
62                                      Several investigational agents with activity against drug-resist
63 led phase 2/3 ACTIV-2 trial, which studied 7 investigational agents with diverse routes of administra
64                                              Investigational agents with novel mechanisms of action a
65 s also an important setting in which to test investigational agents with promising activity, such as
66  models of KRAS(G12D) cancers, including the investigational agent zoldonrasib (RMC-9805) currently u